Author: Poirier L.A. Doerge D.R. Gaylor D.W. Miller M.A. Lorentzen R.J. Casciano D.A. Kadlubar F.F. Schwetz B.A.
Publisher: Academic Press
ISSN: 0273-2300
Source: Regulatory Toxicology and Pharmacology, Vol.30, Iss.3, 1999-12, pp. : 217-222
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
FDA grants priority review for prasugrel
Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. :
USA FDA issues alert about Cylert-associated liver toxicity
Reactions Weekly, Vol. 1, Iss. 1075, 2005-01 ,pp. :
US FDA to review bladder cancer risks for pioglitazone
Reactions Weekly, Vol. 1, Iss. 1320, 2010-01 ,pp. :
Imatinib for priority review by US FDA for GIST recurrence.
Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. :
Treprostinil NDA accepted for review by US FDA.
Inpharma, Vol. 1, Iss. 1655, 2008-01 ,pp. :